Shots:
The US FDA has approved Tryngolza (80mg, QM, self-administered via an auto-injector) as an adj. for reducing triglycerides (TG) in FCS patients, based on a P-III (BALANCE) study. Further submission is under review in the EU, with more filings planned
The P-III study involved FCS patients with fasting TG levels of ≥880mg/dL. Trial showed…
